Portal de Periódicos da CAPES

Prophylaxis with recombinant factor VIIa for the management of bleeding episodes during immune tolerance treatment in a boy with severe haemophilia A and high-response inhibitors

2008; Wiley; Volume: 14; Issue: 5 Linguagem: Inglês

10.1111/j.1365-2516.2008.01767.x

1365-2516

Jan Blatný, Svetlana Kohlerova, Ondřej Zapletal, Veronika Fiamoli, Miroslav Penka, Owen P. Smith,

Coagulation, Bradykinin, Polyphosphates, and Angioedema

HaemophiliaVolume 14, Issue 5 p. 1140-1142 Prophylaxis with recombinant factor VIIa for the management of bleeding episodes during immune tolerance treatment in a boy with severe haemophilia A and high-response inhibitors J. BLATNY, J. BLATNY Department of Clinical Haematology, Centre for Thrombosis and Haemostasis, University Hospital Brno, Czech RepublicSearch for more papers by this authorS. KOHLEROVA, S. KOHLEROVA Department of Clinical Haematology, Centre for Thrombosis and Haemostasis, University Hospital Brno, Czech RepublicSearch for more papers by this authorO. ZAPLETAL, O. ZAPLETAL Department of Clinical Haematology, Centre for Thrombosis and Haemostasis, University Hospital Brno, Czech RepublicSearch for more papers by this authorV. FIAMOLI, V. FIAMOLI Department of Clinical Haematology, Centre for Thrombosis and Haemostasis, University Hospital Brno, Czech RepublicSearch for more papers by this authorM. PENKA, M. PENKA Department of Clinical Haematology, Centre for Thrombosis and Haemostasis, University Hospital Brno, Czech RepublicSearch for more papers by this authorO. SMITH, O. SMITH Haematology Department, Our Lady’s Children’s Hospital Crumlin, Dublin, IrelandSearch for more papers by this author J. BLATNY, J. BLATNY Department of Clinical Haematology, Centre for Thrombosis and Haemostasis, University Hospital Brno, Czech RepublicSearch for more papers by this authorS. KOHLEROVA, S. KOHLEROVA Department of Clinical Haematology, Centre for Thrombosis and Haemostasis, University Hospital Brno, Czech RepublicSearch for more papers by this authorO. ZAPLETAL, O. ZAPLETAL Department of Clinical Haematology, Centre for Thrombosis and Haemostasis, University Hospital Brno, Czech RepublicSearch for more papers by this authorV. FIAMOLI, V. FIAMOLI Department of Clinical Haematology, Centre for Thrombosis and Haemostasis, University Hospital Brno, Czech RepublicSearch for more papers by this authorM. PENKA, M. PENKA Department of Clinical Haematology, Centre for Thrombosis and Haemostasis, University Hospital Brno, Czech RepublicSearch for more papers by this authorO. SMITH, O. SMITH Haematology Department, Our Lady’s Children’s Hospital Crumlin, Dublin, IrelandSearch for more papers by this author First published: 28 August 2008 https://doi.org/10.1111/j.1365-2516.2008.01767.xCitations: 13 Jan Blatny, Consultant Haematologist, Children’s University Hospital, Temple Street, Dublin 1, Ireland.Tel.: +353 1878 4692; fax: +353 8766 78640;e-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Haya S, Moret A, Cid AR et al. Inhibitors in haemophilia A: current management and open issues. Haemophilia 2007; 13: 52–60. 2 O′Connell N, McMahon C, Smith J et al. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors. Br J Haematol 2002; 116: 632–5. 3 Gouw SC, Van Der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with haemophilia A: the CANAL cohort study. Blood 2007; 109: 4648–54. 4 Wight J, Paisley J, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003; 9: 436–63. 5 Saxon BR, Shanks D, Jory CB, Williams V. Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-NovoSeven) in a child with high titre inhibitors and a target joint. Thromb Haemost 2001; 86: 1126–7. 6 Carcao M, St Louis J, Poon MC et al. Rituximab for congential haemophiliacs with inhibitors: a Canadian experience. Haemophilia 2006; 12: 7–18. 7 Morfini M, Auerswald G, Kobelt RA et al. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia 2007; 13: 502–7. 8 Konkle BA, Ebbesen LS, Erhardtsen E et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904–13. 9 Brackmann HH, Effenberger E, Hess L, Schwaab R, Oldenburg J. NovoSeven® in immune tolerance therapy. Blood Coagul Fibrinolysis 2000; 11: 39–44. Citing Literature Volume14, Issue5September 2008Pages 1140-1142 ReferencesRelatedInformation